| Document |
Document Title |
|
WO/2020/012339A1 |
The invention is directed to substituted carbon-linked bicycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (X): (X) wherein C', D', L2', L3', R1', R2', R3', R4', R5', R6', R7', R8', z1', z...
|
|
WO/2020/009016A1 |
The present invention provides a method for producing an organic compound in which functional groups are reacted with each other without the use of a solvent. The present invention pertains to a method for producing an organic compound c...
|
|
WO/2020/010244A1 |
The present disclosure provides compounds for the inhibition of soluble epoxide hydrolase and associate disease conditions, as well as a method of treating or preventing disorders in a subject by inhibition of soluble epoxide hydrolase.
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2019/243414A1 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.
|
|
WO/2019/229464A1 |
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...
|
|
WO/2019/222834A1 |
This application pertains to group 5 metal complexes having the structure of Formula I: and their potential utility in catalyzing amination of polyolefins having alkene groups.amine-
|
|
WO/2019/221192A1 |
The present invention provides a method for producing an amino acid aminoalkyl ester or an inorganic acid salt thereof by reacting a compound represented by general formula (I) or a compound represented by general formula (III), or a sal...
|
|
WO/2019/217509A1 |
The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyi urea or thiorurea compound useful as such agents. The present invention also relates to methods f...
|
|
WO/2019/175799A3 |
The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable sa...
|
|
WO/2019/198592A1 |
A compound represented by formula (I) or a salt thereof. In formula (I), R1 represents a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group or the like; R2 represents a hydrogen atom or a C1-6 alkyl group; each of R3 and R4 i...
|
|
WO/2019/198600A1 |
[Problem] To provide a method for producing urea that curbs corrosion of a urea plant and increases the reaction yield. [Solution] A method for producing urea from raw production materials including NH3 and CO2 at a urea production plant...
|
|
WO/2019/195634A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds...
|
|
WO/2019/178248A1 |
Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.
|
|
WO/2019/164442A1 |
Use of a non-ionic deep eutectic mixture consisting of A and B, A being R1R2N-CO-NR3R4 and B being selected from the group consisting of R5R6N-CO-CH3 and R7R8N-CO-NR9R10, and wherein each of R1-R10 is independently H, CH3 or alkyl, as a ...
|
|
WO/2019/160037A1 |
The purpose of the present invention is to provide methods for producing a carboxamide compound, a sulfonamide compound, and an ester compound using an acid halide. The methods for producing a carboxamide compound, a sulfonamide compound...
|
|
WO/2019/151384A1 |
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...
|
|
WO/2019/137724A1 |
The present invention relates to ureylene additives, a method for their preparation, a use of said ureylene additives favorably as additive in metal or metal alloy deposition composition, preferably in a copper or copper alloy deposition...
|
|
WO/2019/124411A1 |
A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-m
ethylbenzenesulfonic acid or ...
|
|
WO/2019/107322A1 |
A monomer which can yield a cured product having both high toughness and rigidity, a monomer composition containing said monomer, said monomer composition used as a dental material monomer composition, a dental material composition conta...
|
|
WO/2019/106784A1 |
The present invention is provided with a reformer 1 for reforming a hydrocarbon source to obtain hydrogen and carbon dioxide, an ammonia production unit 10 for using the hydrogen and carbon dioxide obtained by the reformer 1 to obtain am...
|
|
WO/2019/106490A1 |
The present invention is directed towards a process for the preparation of Cariprazine (Ia) or a pharmaceutically acceptable salt thereof, wherein, N,N- dimethyl-1H-imidazole-1-carboxamide alkyl halide (VII) is reacted with trans-4- (2-(...
|
|
WO/2019/092253A1 |
The present invention relates to an improved process of preparation of idelalisib using a solid form of intermediate of formula (2); characterized by XRPD pattern having 20 values 5.5°, 10.9°, 14.3°, 16.9° (±0.2) the process compris...
|
|
WO/2019/074822A1 |
The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicam...
|
|
WO/2019/051222A1 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/040109A1 |
Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates an...
|
|
WO/2019/036678A1 |
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
|
|
WO/2019/031470A1 |
[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) o...
|
|
WO/2019/032924A1 |
Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea c...
|
|
WO/2019/027941A1 |
The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
|
|
WO/2019/026994A1 |
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...
|
|
WO/2019/002788A1 |
The invention relates to the use of ureas as extractants for fully or partially separating uranium(VI) from plutonium(IV) in an aqueous solution obtained by dissolving a spent nuclear fuel in nitric acid, by means of liquid-liquid extrac...
|
|
WO/2018/227300A1 |
Novel urea, thiourea and squaramide compounds and bioisosteres thereof of formulas (I) and (VI) and the use thereof for treating, attenuating, inhibiting or preventing inflammation and inflammation-related pathologies are described herein.
|
|
WO/2018/225663A1 |
The purpose of the present invention is to provide a recording material and a recording sheet, in each of which a non-phenolic compound having good color-developing performance and the like is used as a color developer. A compound repres...
|
|
WO/2018/219309A1 |
The present invention relates to a vinylarene derivative which modulates or inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene derivative and the use thereof...
|
|
WO/2018/211953A1 |
The purpose of the present invention is to provide a method for safely and efficiently producing a fluorinated carbonate derivative. This fluorinated carbonate derivative production method is characterized by emitting light in the presen...
|
|
WO/2018/212511A1 |
Provided are: a self-healing polymer network containing a physical crosslinker; and a composition therefor. The self-healing polymer network comprises self-healing monomers having a first polymerizable functional group and at least one u...
|
|
WO/2018/209030A1 |
The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the ...
|
|
WO/2018/189479A1 |
The present invention relates to conjugated polymers supporting chemical probes and the use thereof for the preparation of chemical sensors based on carbon nanotubes allowing the selective detection of analytes in the water.
|
|
WO/2018/187414A1 |
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.
|
|
WO/2018/181986A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/179343A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/172852A1 |
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...
|
|
WO/2018/168573A1 |
When recovering and utilizing the urea and NH3 contained in a gas that contains urea dust and NH3 and has been discharged from a urea granulation step, an aqueous urea solution to be fed to the urea granulation step is prevented from suf...
|
|
WO/2018/170109A1 |
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins - mitoch...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/161033A1 |
Described herein are IRE1-alpha inhibitors, compositions containing such inhibitors, and methods of treatment of cancer that include administration of such compounds. Exemplary compounds are provided throughout the application.
|
|
WO/2018/154560A1 |
The invention provides aqueous hydrohalide liquid compositions containing more than 50% hydrohalide and less than 8% water. A method is provided for preparing a composition containing up to 95% urea hydrobromide, which is liquid at ambie...
|
|
WO/2018/148737A1 |
The present invention is directed to the use of a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of the symptoms of dementia with Lewy bodies, Parkinson's disease, or a combination thereof in an individual...
|
